How long should patients with leukemia take venetoclax/venetoclax?

Venetoclax/Venetoclax (Venetoclax) is a drug for the treatment of various leukemias, and its application in the treatment of leukemia has received widespread attention. However, the duration of venetoclax use in patients with leukemia is a complex and individualized issue and no generalization can be made.

The dosage regimen of venetoclax usually needs to be formulated based on the patient's specific situation. Generally, the treatment cycle with venetoclax consists of a dose escalation phase and a maintenance phase. During the dosage increase period, doctors will gradually adjust the dosage of the drug based on the patient's tolerance and disease response to achieve the best therapeutic effect. During the maintenance period, patients usually need to continue taking venetoclax to maintain the stability of their condition.

Veneclat is effective in chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) and acute myeloid leukemia (AML). Venetoclax also works quickly, with many people taking an average of a month to feel a slowdown in disease progression. If the patient has untreated CLL or SLL, venetoclax is usually given in combination with obinutuzumab for 12 months; if the patient has been previously treated, venetoclax is usually given in combination with rituximab for up to 24 months; for patients with AML, treatment is continued until disease progression or unacceptable toxicity is observed, as long as the physician deems it safe.

Although venetoclax is an effective treatment, it also has certain side effects and risks. Therefore, patients need to pay close attention to their physical condition during the use of venetoclax and report any discomfort or abnormal reactions to their doctor in a timely manner. At the same time, doctors will also provide personalized guidance and suggestions based on the patient's specific situation and needs.